Document is current
Any future updates will be listed below
-
Authors
Heidinger, Martin https://orcid.org/0000-0003-2816-1351
Maggi, Nadia https://orcid.org/0000-0002-9483-0245
Dutilh, Gilles https://orcid.org/0000-0002-6719-2508
Mueller, Madleina
Eller, Ruth S. https://orcid.org/0000-0003-0573-4452
Loesch, Julie M.
Schwab, Fabienne D. https://orcid.org/0000-0003-1124-3780
Kurzeder, Christian
Weber, Walter P.
-
Funding
Funding for this research was provided by:
University of Basel
- License Information
-
More Information
Article History
Received: 15 March 2023
Accepted: 4 June 2023
First Online: 8 June 2023
Declarations
:
: This research project complies with the guidelines for human studies according to the Declaration of Helsinki as revised in 2013. The study protocol was approved by the Ethics Committee of Northwest and Central Switzerland (Ethikkommission Nordwest und Zentralschweiz, EKNZ, Approval number 2016–01525).
: Written informed consent was obtained from all individual participants included in the study.
: CK: Christian Kurzeder received consulting fees from GSK, Astra Zeneca, Novartis, Roche, Eli Lilly S.A., Pfizer, Genomic Health, Merck MSD, Novartis, PharmaMar, Tesaro; sits on advisory boards of GSK, Astra Zeneca, Novartis, Roche, Eli Lilly S.A., Pfizer, Genomic Health, Merck MSD, Novartis, PharmaMar, Tesaro; received travel support from GSK, Astra Zeneca, Roche. WW: W.P. Weber received research support from Agendia paid to the University Hospital Basel for the TAXIS study (OPBC-03, SAKK 23/16, IBCSG 57–18, ABCSG-53, GBG 101).
